Skip to main content

Wezlana FDA Approval History

Last updated by Judith Stewart, BPharm on April 30, 2025.

FDA Approved: Yes (First approved October 31, 2023)
Brand name: Wezlana
Generic name: ustekinumab-auub
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis

Wezlana (ustekinumab-auub) is a human interleukin-12 and -23 antagonist biosimilar/interchangeable to Stelara used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Development timeline for Wezlana

DateArticle
Oct 31, 2023Approval FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
Apr 18, 2022Amgen Announces Positive Top-Line Results From Phase 3 Study of ABP 654, Biosimilar Candidate to Stelara® (ustekinumab)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.